1. Use of terbutaline in the treatment of complete heart block in the fetus.
- Author
-
Robinson BV, Ettedgui JA, and Sherman FS
- Subjects
- Dose-Response Relationship, Drug, Echocardiography, Female, Fetal Diseases diagnosis, Fetal Diseases mortality, Fetal Heart diagnostic imaging, Gestational Age, Heart Block diagnosis, Heart Block mortality, Heart Rate drug effects, Heart Rate physiology, Humans, Hydrops Fetalis etiology, Hydrops Fetalis mortality, Infant Welfare, Infant, Newborn, Male, Noonan Syndrome drug therapy, Noonan Syndrome etiology, Noonan Syndrome mortality, Pennsylvania, Pregnancy, Pregnancy Complications, Cardiovascular diagnosis, Pregnancy Complications, Cardiovascular drug therapy, Respiratory Distress Syndrome, Newborn drug therapy, Respiratory Distress Syndrome, Newborn etiology, Respiratory Distress Syndrome, Newborn mortality, Survival Analysis, Treatment Outcome, Women's Health, Adrenergic beta-Agonists therapeutic use, Fetal Diseases drug therapy, Fetal Heart abnormalities, Heart Block drug therapy, Terbutaline therapeutic use
- Abstract
Between 1989 and 2000, 21 fetuses were diagnosed with complete atrioventricular block. Seven women with fetal ventricular rates of less than 60 were given oral terbutaline, and 6 of these had an initial increase in the fetal ventricular rate. Four fetuses (57%) maintained an increased average rate of 60 beats per minute and survived. Two fetuses returned to rates below 55 and died. The final fetus, with hypertrophic cardiomyopathy, was unresponsive. Terbutaline, therefore, is initially effective in raising the fetal ventricular rate, but this effect may be transient.
- Published
- 2001
- Full Text
- View/download PDF